# US 2026/0007630 A1 · Compositions comprising selective androgen receptor modulator compounds in combination with weight loss drugs and uses thereof for quality weight loss

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0007630 A1
- Document ID: US20260007630A1
- Status: Published application
- Kind: A1
- Application number: 19/319,108
- Filed: 2025-09-04
- Published: 2026-01-08
- Earliest claimed: 2023-10-03
- Assignees: Veru Inc.
- Applicants: Veru Inc.
- Inventors: Mitchell S. STEINER; Kester Gary BARNETTE
- Web page: https://patentgrep.com/patent/US20260007630A1

## CPC

- A61K 31/277: having a ring, e.g. verapamil
- A61K 38/26: Glucagons
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/06: Anabolic agents (androgens A61P5/26)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the field of treatment for body composition changes in weight management. In some embodiments, the present invention provides compositions and methods for mitigating the adverse effects of treatment by weight loss drugs that suppress appetite including incretin agonist or antagonist containing drugs such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or by sodium-glucose transport protein 2 (SGLT-2) inhibitors. In one embodiment, the present invention provides a composition of semaglutide and a selective androgen receptor modulator (SARM) compound of Formula IX.

## Claims

### Claim 1

A composition comprising a pharmaceutical composition of Formula IX, or an optical isomer, a racemic mixture, a pharmaceutically acceptable salt, a pharmaceutical product, a hydrate, an N-oxide, or a crystal thereof; and a pharmaceutical composition of semaglutide:

### Claim 2 (depends on 1)

A method for reducing or treating adverse effects caused by semaglutide monotherapy, comprising co-administering to the subject the pharmaceutical composition of Formula IX and the pharmaceutical composition of semaglutide of the composition of claim 1.

### Claim 3 (depends on 2)

The method according to claim 2, wherein (i) the subject has obesity and (ii) the subject is 60 years old or older.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the adverse effects comprise one or more of loss in (i) lean body mass, fat-free mass, or muscle mass, (ii) muscle strength, and (iii) physical function.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the loss in lean body mass is from about 3% to 20% of the total body weight in the subject.

### Claim 6 (depends on 2)

The method according to claim 2, wherein the method results in one or more of (i) reducing the loss of lean body mass, preserving lean body mass, or gaining lean body mass (muscle mass) in the subject, (ii) reversing bone loss or gaining bone in the subject, (iii) overcoming or improving insulin resistance in the subject, and (iv) improving HbA1c in the subject.

### Claim 7 (depends on 2)

The method according to claim 2, wherein the method results in one or more of reducing abdominal, subcutaneous, or intramuscular fat accumulation, improving body composition, lowering body fat content, lowering fat mass, or increasing or preserving muscle mass or muscle strength or muscle physical function in the subject.

### Claim 8 (depends on 2)

The method according to claim 2, wherein the method results in preservation or restoration of lean body mass (LBM) or muscle in the subject, or wherein the method enhances fat loss or prevents fat regain.

### Claim 9 (depends on 2)

The method according to claim 2, wherein the method reduces or treats muscle weakness, poor balance, decreased gait speed, mobility disability, loss of independence, increased risk of falls, bone fractures, loss of physical function, physical disability, poor quality of life, high hospitalization rates, and/or increased mortality in the subject.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the bone fractures are fractures of the hip or pelvis in the subject.

### Claim 11 (depends on 2)

The method according to claim 2, wherein the Formula IX is administered to the subject concurrently with or after the treatment with the semaglutide.

### Claim 12 (depends on 2)

The method according to claim 2, wherein said method reduces or treats lean mass loss in a subject who is under treatment or stops treatment with the semaglutide.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the method decreases fat mass while preserving or increasing lean mass in the subject.

### Claim 14 (depends on 12)

The method according to claim 12, wherein the method improves physical function.

### Claim 15 (depends on 12)

The method according to claim 12, further reducing and treating muscle weakness, poor balance, decreased gait speed, mobility disability, loss of independence, increased risk of falls, bone fractures, loss of physical function, physical disability, poor quality of life, high hospitalization rates, and/or increased mortality in the subject.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the bone fractures are fractures of the hip or pelvis in the subject.

### Claim 17 (depends on 1)

A method for maintenance or improvement of body composition compared to semaglutide monotherapy, comprising co-administering to the subject the pharmaceutical composition of Formula IX and the pharmaceutical composition of semaglutide of the composition of claim 1.

### Claim 18 (depends on 17)

The method for maintenance or improvement of body composition according to claim 17, wherein the subject discontinues semaglutide, but continues treatment with Formula IX, or an optical isomer, a racemic mixture, a pharmaceutically acceptable salt, a pharmaceutical product, a hydrate, an N-oxide, or a crystal thereof, as monotherapy:

### Claim 19 (depends on 17)

The method according to claim 17, wherein said improved body composition is represented by further decreasing fat mass while preserving or increasing lean mass in a subject who is under treatment with said co-administered semaglutide and Formula IX or stops treatment with semaglutide, relative to a subject who is under treatment with the semaglutide alone.

### Claim 20 (depends on 17)

The method according to claim 17, wherein said improved body composition is represented by further decreasing fat mass while preserving or increasing lean mass in a subject who was co-administered the semaglutide and the Formula IX, and then said semaglutide is discontinued; relative to a subject who is under treatment with the semaglutide alone.

### Claim 21 (depends on 17)

The method according to claim 17, wherein the physical function or muscle strength is maintained or improved.

### Claim 22 (depends on 17)

The method according to claim 17, wherein (i) the subject has obesity and (ii) the subject is 60 years old or older.

### Claim 23 (depends on 17)

The method according to claim 17, wherein the method reduces or treats rebound of one or more of (i) weight gain, (ii) fat mass gain, and (iii) lean mass loss when the semaglutide is discontinued.

### Claim 24 (depends on 17)

The method according to claim 17, wherein the method results in preservation or restoration of lean body mass (LBM) or muscle in the subject.

### Claim 25 (depends on 17)

The method according to claim 17, wherein said method augments fat loss or prevents fat regain.

### Claim 26 (depends on 1)

The composition according to claim 1, wherein the Formula IX is formulated for administration at a dose of from 0.1 mg to 50 mg per day, or wherein the Formula IX is formulated for administration at a dose of 3 mg per day or 6 mg per day, and wherein the semaglutide is formulated for administration at the dose of from 0.25 mg per week to 1.7 mg per week.

### Claim 27 (depends on 1)

A method of reducing or treating rebound in a subject in need thereof, wherein the rebound is in one or more of (i) weight gain, (ii) fat mass gain, and (iii) lean mass loss when the semaglutide is discontinued in said subject but Formula IX treatment continues as monotherapy:
wherein the subject was previously administered the composition of claim 1.

### Claim 28 (depends on 27)

The method according to claim 27, wherein the method results in preservation or restoration of lean body mass (LBM) or muscle in the subject, or wherein the method enhances fat loss or prevents fat regain.

### Claim 29 (depends on 27)

The method according to claim 27, wherein the Formula IX is administered to the subject concurrently with or after the treatment with the semaglutide.

### Claim 30 (depends on 27)

The method according to claim 27, wherein said method reduces or treats lean mass loss in a subject who is under treatment or stops treatment with the semaglutide.
